Estimands and Complex Innovative Designs
Open Access
- 29 March 2022
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 112 (6) , 1183-1190
Abstract
Since the release of the ICH E9(R1) (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials) document in 2019, the estimand framework has become a fundamental part of clinical trial protocols. In parallel, complex innovative designs have gained increased popularity in drug development, in particular in early development phases or in difficult experimental situations. While the estimand framework is relevant to any study in which a treatment effect is estimated, experience is lacking as regards its application to these designs. In a basket trial for example, should a different estimand be specified for each subpopulation of interest, defined, for example, by cancer site? Or can a single estimand focusing on the general population (defined, for example, by the positivity to a certain biomarker) be used? In the case of platform trials, should a different estimand be proposed for each drug investigated? In this work we discuss possible ways of implementing the estimand framework for different types of complex innovative designs. We consider trials that allow adding or selecting experimental treatment arms, modifying the control arm or the standard of care, and selecting or pooling populations. We also address the potentially data‐driven, adaptive selection of estimands in an ongoing trial and disentangle certain statistical issues that pertain to estimation rather than to estimands, such as the borrowing of nonconcurrent information. We hope this discussion will facilitate the implementation of the estimand framework and its description in the study protocol when the objectives of the trial require complex innovative designs.Keywords
This publication has 50 references indexed in Scilit:
- Twenty‐five years of confirmatory adaptive designs: opportunities and pitfallsStatistics in Medicine, 2015
- Adaptive seamless designs with interim treatment selection: a case study in oncologyStatistics in Medicine, 2015
- Robust meta‐analytic‐predictive priors in clinical trials with historical control informationBiometrics, 2014
- Simultaneous confidence intervals that are compatible with closed testing in adaptive designsBiometrika, 2013
- Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interimPharmaceutical Statistics, 2011
- An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints†Pharmaceutical Statistics, 2010
- Selection and bias—Two hostile brothersStatistics in Medicine, 2009
- Adaptive designs for confirmatory clinical trialsStatistics in Medicine, 2009
- Testing and estimation in flexible group sequential designs with adaptive treatment selectionStatistics in Medicine, 2005
- PLANNING AND REVISING THE SAMPLE SIZE FOR A TRIALStatistics in Medicine, 1995